Discovery of a potent parenterally administered factor XIa inhibitor with hydroxyquinolin-2(1H)-one as the P2′ moiety

ACS Medicinal Chemistry Letters

Volumn 6, Issue 5, 2015, Pages 590-595

  Hu, Zilun ^a   Wong, Pancras C ^a   Gilligan, Paul J ^a   Han, Wei ^a   Pabbisetty, Kumar B ^a   Bozarth, Jeffrey M ^a   Crain, Earl J ^a   Harper, Timothy ^a   Luettgen, Joseph M ^a   Myers, Joseph E ^a   Ramamurthy, Vidhyashankar ^a   Rossi, Karen A ^a   Sheriff, Steven ^a   Watson, Carol A ^a   Wei, Anzi ^a   Zheng, Joanna J ^a   Seiffert, Dietmar A ^a   Wexler, Ruth R ^a   Quan, Mimi L ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

anticoagulant; factor XIa; Thrombosis

Indexed keywords

AMIDE; BLOOD CLOTTING INHIBITOR; FACTOR XIA INHIBITOR; HYDROXYL GROUP; IMIDAZOLE DERIVATIVE; PHENYLALANINE; PIPERAZINE; QUINOLINE DERIVATIVE; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; EC50; ENZYME BINDING; HUMAN; HUMAN CELL; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE;

ORYCTOLAGUS CUNICULUS;

EID: 84929302673     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00066     Document Type: Article

References (28)

1. Ansell, J.; Hirsh, J.; Hylek, E.; Jacobson, A.; Crowther, M.; Palareti, G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition) Chest 2008, 133, 160S-198S
2. Stein, P. D.; Grandison, D.; Hua, T. A. Therapeutic level of anticoagulation with warfarin in patients with mechanical prosthetic heart valves: review of literature and recommendations based on internal normalized ratio Postgrad. Med. J. 1994, 70 (suppl 1) S72-S83
3. Hirsh, J.; Poller, L. The international normalized ratio. A guide to understanding and correcting its problems Arch. Int. Med. 1994, 154, 282-288
4. Yeh, C. H.; Fredenburgh, J. C.; Weitz, J. I. Oral direct factor Xa inhibitors Circ. Res. 2012, 111 (8) 1069-1078
5. Spinler, S. The pharmacology and therapeutic use of dabigatran etexilate J. Clin. Pharmacol. 2013, 53 (1) 1-13
6. Pinto, D. J. P.; Wong, P. C.; Knabb, R. M.; Wexler, R. R. Case history: Eliquis (Apixaban), a potent and selective inhibitor of coagulation factor Xa for the prevention and treatment of thrombotic diseases Annu. Rep. Med. Chem. 2012, 47, 123-139
7. Granger, C. B.; Alexander, J. H.; McMurray, J. J.; Lopes, R. D.; Hylek, E. M.; Hanna, M.; Al-Khalidi, H. R.; Ansell, J.; Atar, D.; Avezum, A.; Bahit, M. C.; Diaz, R.; Easton, J. D.; Ezekowitz, J. A.; Flaker, G.; Garcia, D.; Geraldes, M.; Gersh, B. J.; Golitsyn, S.; Goto, S.; Hermosillo, A. G.; Hohnloser, S. H.; Horowitz, J.; Mohan, P.; Jansky, P.; Lewis, B. S.; Lopez-Sendon, J. L.; Pais, P.; Parkhomenko, A.; Verheugt, F. W.; Zhu, J.; Wallentin, L. Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 2011, 365 (11) 981-992
8. Perzborn, E.; Roehring, S.; Straub, A.; Kubitza, D.; Misselwitz, F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor Nat. Rev. Drug Discovery 2011, 10, 61-75
9. Straub, A.; Roehrig, S.; Hillisch, A. Entering the era of non-basic P1 site groups: discovery of Xarelto (Rivaroxaban) Curr. Top. Med. Chem. 2010, 10, 257-269
10. Franchini, M.; Veneri, D.; Lippi, G. Inherited factor XIa deficiency: a concise review Hematology 2006, 11, 307-309
11. Gailani, D.; Lasky, N.; Broze, G. A murine model of factor XI deficiency Blood Coagulation Fibrinolysis 1997, 8, 134-144
12. Wang, X.; Cheng, I.; Xu, I.; Feuerstein, G. Z.; Hsu, M.-Y.; Smith, P. L.; Seiffert, D.; Schumacher, W. A.; Ogletree, M. L.; Gailani, D. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice J. Thromb. Haemostasis 2005, 3, 695-702
13. Rosen, E. D.; Gailani, D.; Castellino, J. F. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse Thromb. Haemostasis 2002, 87, 774
14. Schumacher, W.; Luettgen, J.; Quan, M. L.; Seiffert, D. Inhibition of factor XIa as a new approach to anticoagulant Arterioscler. Thromb. Vasc. Biol. 2010, 30, 388-392
15. van Montfoort, M. L.; Meijers, J. C. M. Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway? Thromb. Haemostasis 2013, 110, 223-232
16. Löwenberg, E. C.; Meijers, J. C. M.; Monia, B. P.; Levi, M. Coagulation factor XI as a novel target for antithrombotic treatment J. Thromb. Haemostasis 2010, 8, 2349-2357
17. Büller, H. R.; Bethune, C.; Bhanot, S.; Gailani, D.; Monia, B. P.; Raskob, G. E.; Segers, A.; Verhamme, P.; Weitz, J. I. Factor XI antisense oligonucleotide for prevention of venous thrombosis N. Engl. J. Med. 2015, 372, 233-240 This was published after this work was complete.
18. Quan, M.; Wong, P. C.; Wang, C.; Woerner, F.; Smallheer, J. M.; Barbera, F. A.; Bozarth, J. M.; Brown, R. L.; Harpel, M. R.; Luettgen, J. M.; Morin, P. E.; Peterson, T.; Ramamurthy, V.; Rendina, A. R.; Rossi, K. A.; Watson, C. A.; Wei, A.; Zhang, G.; Seiffert, D.; Wexler, R. R. Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors J. Med. Chem. 2014, 57, 955-969
19. Wong, P. C.; Quan, M. L.; Watson, C.; Crain, E.; Wexler, R. R.; Seiffert, D. Potent antithrombotic effect of a small-molecule, reversible and direct inhibitor of factor XIa with minimum bleeding time effect in rabbit models of arterial thrombosis and hemostasis; AHA: Dallas, TX, Nov. 2013; APS.709.03, Poster 7050.
20. Hangeland, J. J.; Friends, T. J.; Rossi, K. A.; Smallheer, J. M.; Wang, C.; Sun, Z.; Corte, J. R.; Fanf, T.; Wong, P. C.; Rendina, A. R.; Barbera, F. A.; Bozarth, J. M.; Luettgen, J. M.; Watson, C. A.; Zhang, G.; Wei, A.; Morin, P. E.; Bisacchi, G. S.; Seiffert, D.; Wexler, R. R.; Quan, M. L. Optimization of phenylimidazole coagulation Factor XIa inhibitors: discovery of trans -N-((S)-1-(4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl)-2-phenylethyl)-4-(aminomethyl)cyclo-hexanecarboxamide, a potent Factor XIa inhibitor with in vivo antithrombotic activity J. Med. Chem. 2014, 57, 9915-9932
21. Pinto, D. J. P.; Smallheer, J. M.; Corte, J. R.; Austin, E. J. D.; Wang, C.; Fang, T.; Smith, L. M., II; Rossi, K. A.; Rendina, A. R.; Bozarth, J. M.; Zhang, G.; Wei, A.; Ramamurthy, V.; Sheriff, S.; Myers, J. E., Jr; Morin, P. E.; Luettgen, J. M.; Seiffert, D. A.; Quan, M. L.; Wexler, R. R. Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties Bioorg. Med. Chem. Lett. 2015, 25, 1635-1642
22. McNaney, C. A.; Dexler, D. M.; Hnatyshyn, S. Y.; Zvyaga, T. A.; Knipe, J. O.; Belcastro, J. V.; Sanders, M. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion Assay Drug Dev. Technol. 2008, 6, 121-129
23. Baston, E.; Palusczak, A.; Hartmann, R. W. 6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5-alpha reductases types 1 and 2 Eur. J. Med. Chem. 2000, 35, 931-940
24. Gordon, T. D.; Singh, J.; Hansen, P. E.; Morgan, B. A. Synthetic approaches to the 'Azole' peptide mimetics Tetrahedron Lett. 1993, 34, 1901-1904
25. Björkqvist, J.; Jämsä, A.; Renné, T. Plasma kallikrein: the bradykinin-producing enzyme Thromb. Haemostasis 2013, 110, 399-407
26. Feener, E. P.; Zhou, Q.; Fickweiler, W. Role of plasma kallikrein in diabetes and metabolism Thromb. Haemostasis 2013, 110, 434-441
27. Wong, P. C.; Crain, E. J.; Knabb, R. M.; Meade, R. P.; Quan, M. L.; Watson, C. A.; Wexler, R. R.; Wright, M. R.; Slee, A. M. Electrically Induced Carotid Artery Thrombosis J. Pharmacol. Exp. Ther. 2000, 295, 212-218
28. Wong, P. C.; Crain, E. J.; Watson, C. A.; Zaspel, A. M.; Wright, M. R.; Lam, P. K.; Pinto, D. J. P.; Wexler, R. R.; Knabb, R. M. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits J. Pharmacol. Exp. Ther. 2002, 303, 993-1000